Your email has been successfully added to our mailing list.

×
0 -0.0024390243902439 -0.0024390243902439 -0.0024390243902439 -0.0024390243902439 -0.0024390243902439 -0.0024390243902439 0.00721951219512204
Analyst impact report

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at Morgan Stanley to an "equal weight" rating. They now have a $112.00 price target on the s

Neurocrine Biosciences, Inc. (NBIX)  More Company Research Source: MarketBeat
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: neurocrine.com/about-us/webcasts-presentations
Impact snapshot Event time: NBIX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
NBIX alerts
from News Quantified
Opt-in for
NBIX alerts

from News Quantified
Opt-in for
NBIX alerts

from News Quantified